| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | DG58 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA963 | | |
| Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer | IPG784 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | HTE12 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | DG56 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer | TA909 | | |
| Irreversible electroporation for treating prostate cancer | IPG768 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | IPG763 | | |
| Transperineal biopsy for diagnosing prostate cancer | DG54 | | |
| MRI fusion biopsy systems for diagnosing prostate cancer | DG53 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | IPG756 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | IPG757 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | IPG752 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | MTG72 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA823 | | |
| Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | DG46 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Microwave ablation for primary or metastatic cancer in the lung | IPG716 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (terminated appraisal) | TA762 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA761 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA760 | | |
| Transanal total mesorectal excision for rectal cancer | IPG713 | | |
| Colorectal cancer | NG151 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | IPG691 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | IPG686 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| Testing strategies for Lynch syndrome in people with endometrial cancer | DG42 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Irreversible electroporation for primary liver cancer | IPG664 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA611 | | |
| Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer | IPG659 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | IPG656 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | IPG638 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | IPG628 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA529 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Cancer of the upper aerodigestive tract: assessment and management in people aged 16 and over | NG36 | | |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer | IPG614 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Pancreatic cancer in adults: diagnosis and management | NG85 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Tests in secondary care to identify people at high risk of ovarian cancer | DG31 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Irreversible electroporation for treating pancreatic cancer | IPG579 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Molecular testing strategies for Lynch syndrome in people with colorectal cancer | DG27 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer | TA395 | | |
| Haematological cancers: improving outcomes | NG47 | | |
| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer | TA389 | | |
| Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) | TA23 | | |
| Skin cancer prevention | PH32 | | |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA377 | | |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy | TA378 | | |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy | TA374 | | |
| VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions | DG19 | | |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) | TA362 | | |
| Low energy contact X-ray brachytherapy (the Papillon technique) for early stage rectal cancer | IPG532 | | |
| Preoperative high dose rate brachytherapy for rectal cancer | IPG531 | | |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) | TA353 | | |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer | TA347 | | |
| Bladder cancer: diagnosis and management | NG2 | | |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) | TA334 | | |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy | TA323 | | |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen | TA316 | | |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer | TA310 | | |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy | TA307 | | |
| EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer | DG9 | | |
| Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer | DG8 | | |
| Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer | TA284 | | |
| Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer | TA285 | | |
| Irreversible electroporation for treating primary lung cancer and metastases in the lung | IPG441 | | |
| Irreversible electroporation for treating renal cancer | IPG443 | | |
| Neutropenic sepsis: prevention and management in people with cancer | CG151 | | |
| Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer | TA263 | | |
| Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 | TA257 | | |
| Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer | TA258 | | |
| Focal therapy using cryoablation for localised prostate cancer | IPG423 | | |
| Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy | TA242 | | |
| Breast reconstruction using lipomodelling after breast cancer treatment | IPG417 | | |
| Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer | TA118 | | |
| Fulvestrant for the treatment of locally advanced or metastatic breast cancer | TA239 | | |
| Laparoscopic cryotherapy for renal cancer | IPG405 | | |
| Percutaneous cryotherapy for renal cancer | IPG402 | | |
| Ambulight PDT for the treatment of non-melanoma skin cancer | MTG6 | | |
| Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer | TA227 | | |
| Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer | TA214 | | |
| Percutaneous radiofrequency ablation for primary or secondary lung cancers | IPG372 | | |
| Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer | TA212 | | |
| Trastuzumab for the treatment of HER2-positive metastatic gastric cancer | TA208 | | |
| Laparoscopic hysterectomy (including laparoscopic total hysterectomy and laparoscopically assisted vaginal hysterectomy) for endometrial cancer | IPG356 | | |
| Percutaneous radiofrequency ablation for renal cancer | IPG353 | | |
| Capecitabine for the treatment of advanced gastric cancer | TA191 | | |
| Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer | TA192 | | |
| Topotecan for the treatment of relapsed small-cell lung cancer | TA184 | | |
| Topotecan for the treatment of recurrent and stage IVB cervical cancer | TA183 | | |
| Pemetrexed for the first-line treatment of non-small-cell lung cancer | TA181 | | |
| Ex-vivo hepatic resection and reimplantation for liver cancer | IPG298 | | |
| Endoscopic mastectomy and endoscopic wide local excision for breast cancer | IPG296 | | |
| Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision | IPG268 | | |
| Laparoscopic gastrectomy for cancer | IPG269 | | |
| Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal) | TA148 | | |
| Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck | TA145 | | |
| Pemetrexed for the treatment of non-small-cell lung cancer | TA124 | | |
| Palliative photodynamic therapy for advanced oesophageal cancer | IPG206 | | |
| Gemcitabine for the treatment of metastatic breast cancer | TA116 | | |
| Photodynamic therapy for early-stage oesophageal cancer | IPG200 | | |
| Laparoscopic surgery for colorectal cancer | TA105 | | |
| Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | TA101 | | |
| High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer | IPG174 | | |
| Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer | TA100 | | |
| Laparoscopic retroperitoneal lymph node dissection for testicular cancer | IPG158 | | |
| Endoscopic axillary lymph node retrieval for breast cancer | IPG147 | | |
| Photodynamic therapy for localised inoperable endobronchial cancer | IPG137 | | |
| Cryotherapy as a primary treatment for prostate cancer | IPG145 | | |
| Improving outcomes in children and young people with cancer | CSG7 | | |
| Low dose rate brachytherapy for localised prostate cancer | IPG132 | | |
| Photodynamic therapy for bile duct cancer | IPG134 | | |
| Cryotherapy for recurrent prostate cancer | IPG119 | | |
| Guidance on the use of paclitaxel in the treatment of ovarian cancer | TA55 | | |
| High-intensity focused ultrasound for prostate cancer | IPG118 | | |
| Improving outcomes in head and neck cancers | CSG6 | | |
| Interstitial laser therapy for breast cancer | IPG89 | | |
| Improving supportive and palliative care for adults with cancer | CSG4 | | |
| Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer | TA61 | | |
| Improving outcomes in urological cancers | CSG2 | | |
| Improving outcomes in breast cancer | CSG1 | | |
| Guidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | | |